Cancer Cell 2017-07-10

Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and CHAARTED Studies

Eric J. Small

Index: 10.1016/j.ccell.2017.06.007

Full Text: HTML

Abstract

Two papers published recently in theNew England Journal of Medicinedescribe the utility of abiraterone acetate, an androgen biosynthesis inhibitor, in the early treatment of metastatic prostate cancer. In addition to establishing a new standard of care, these two articles pose a number of important questions for future investigation.

Latest Articles:

HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL

2017-07-10

[10.1016/j.ccell.2017.06.008]

MUC-king with HIF May Rewire Pyrimidine Biosynthesis and Curb Gemcitabine Resistance in Pancreatic Cancer

2017-07-10

[10.1016/j.ccell.2017.06.006]

Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology

2017-07-10

[10.1016/j.ccell.2017.06.005]

MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer

2017-07-10

[10.1016/j.ccell.2017.06.004]

Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment

2017-07-10

[10.1016/j.ccell.2017.06.003]

More Articles...